Now Reading
Researchers Make Breakthrough in Treating Lou Gehrig’s Disease

Researchers Make Breakthrough in Treating Lou Gehrig’s Disease

Amyotrophic lateral sclerosis MRI (axial FLAIR...
Amyotrophic lateral sclerosis MRI (axial FLAIR) demonstrates increased T2 signal within the posterior part of the internal capsule, consistent with the clinical diagnosis of ALS source:Radiopedia.org (Photo credit: Wikipedia)

UCSD scientists announced last week that a metabolism-boosting protein, PCG-1?, may help restore cell function in individuals afflicted by Lou Gehrig’s Disease.

Lou Gehrig’s disease, or Amyotrophic Lateral Sclerosis is a progressive, fatal, adult-onset disease that occurs in roughly 0.0015 percent of the human population, and roughly the same percent of the population in mice — the model organism that was used in the UCSD study.

About 5,500 people die from ALS each year. Humans afflicted with ALS generally begin to see symptoms in their late forties and live only three to five years after diagnosis. Most mice begin exhibiting symptoms of ALS at three or four months, and live a few weeks at most.

The medication Rilutek is the only extant treatment for ALS aside from pain medication. Rilutek can extend survival times for many late stage ALS patients by months. It does not provide any relief from symptoms.

A faulty enzyme, copper-zinc superoxide dismutase (SOD1) is implicated in both mouse and human ALS. How a faulty copy of SOD1 causes ALS remains unknown, however.

The researchers tested the muscle and cardiovascular functioning of the mice to see if there were any significant physiological differences between normal mice that didn’t have ALS and ALS-positive mice that were injected with the gene for PCG-1?.

ALS-positive mice of both varieties were also made to run on small treadmills until they fell off and even electrical shocks would not compel them to get back up and keep running.

The team used two dyes, hematoxylin and eosin, to determine what fraction muscle cells in a tissue were actively performing mitosis at a given time.

ALS-positive mice that had not received any treatment demonstrated slower response times, diminished endurance and reduced rate of mitosis, or cell reproduction. ALS-positive mice that had been treated with PCG-1?, on the other hand, demonstrated none of these deficiencies. In fact, they performed as well on the fitness tests as normal mice without ALS.

See Also

Read more . . .

via UCSD Guardian – Ayan Kusari

Bookmark this page for “ALS Breakthrough” and check back regularly as these articles update on a very frequent basis. The view is set to “news”. Try clicking on “video” and “2” for more articles.

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top